• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从健康衰老到阿尔茨海默病海马体纹理的纵向变化。

Longitudinal changes in hippocampal texture from healthy aging to Alzheimer's disease.

作者信息

Wearn Alfie, Raket Lars Lau, Collins D Louis, Spreng R Nathan

机构信息

Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4.

Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund SE-221 00, Sweden.

出版信息

Brain Commun. 2023 Jul 5;5(4):fcad195. doi: 10.1093/braincomms/fcad195. eCollection 2023.

DOI:10.1093/braincomms/fcad195
PMID:37465755
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10351670/
Abstract

Early detection of Alzheimer's disease is essential to develop preventive treatment strategies. Detectible change in brain volume emerges relatively late in the pathogenic progression of disease, but microstructural changes caused by early neuropathology may cause subtle changes in the MR signal, quantifiable using texture analysis. Texture analysis quantifies spatial patterns in an image, such as smoothness, randomness and heterogeneity. We investigated whether the MRI texture of the hippocampus, an early site of Alzheimer's disease pathology, is sensitive to changes in brain microstructure before the onset of cognitive impairment. We also explored the longitudinal trajectories of hippocampal texture across the Alzheimer's continuum in relation to hippocampal volume and other biomarkers. Finally, we assessed the ability of texture to predict future cognitive decline, over and above hippocampal volume. Data were acquired from the Alzheimer's Disease Neuroimaging Initiative. Texture was calculated for bilateral hippocampi on 3T T-weighted MRI scans. Two hundred and ninety-three texture features were reduced to five principal components that described 88% of total variance within cognitively unimpaired participants. We assessed cross-sectional differences in these texture components and hippocampal volume between four diagnostic groups: cognitively unimpaired amyloid-β ( = 406); cognitively unimpaired amyloid-β ( = 213); mild cognitive impairment amyloid-β ( = 347); and Alzheimer's disease dementia amyloid-β ( = 202). To assess longitudinal texture change across the Alzheimer's continuum, we used a multivariate mixed-effects spline model to calculate a 'disease time' for all timepoints based on amyloid PET and cognitive scores. This was used as a scale on which to compare the trajectories of biomarkers, including volume and texture of the hippocampus. The trajectories were modelled in a subset of the data: cognitively unimpaired amyloid-β ( = 345); cognitively unimpaired amyloid-β ( = 173); mild cognitive impairment amyloid-β ( = 301); and Alzheimer's disease dementia amyloid-β ( = 161). We identified a difference in texture component 4 at the earliest stage of Alzheimer's disease, between cognitively unimpaired amyloid-β and cognitively unimpaired amyloid-β older adults (Cohen's = 0.23, = 0.014). Differences in additional texture components and hippocampal volume emerged later in the disease continuum alongside the onset of cognitive impairment ( = 0.30-1.22, < 0.002). Longitudinal modelling of the texture trajectories revealed that, while most elements of texture developed over the course of the disease, noise reduced sensitivity for tracking individual textural change over time. Critically, however, texture provided additional information than was provided by volume alone to more accurately predict future cognitive change ( = 0.32-0.63, < 0.0001). Our results support the use of texture as a measure of brain health, sensitive to Alzheimer's disease pathology, at a time when therapeutic intervention may be most effective.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/2bdfa4597abf/fcad195f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/b2ed943217b2/fcad195_ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/be646a8ad937/fcad195f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/10b2069557be/fcad195f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/fbfcf4f09176/fcad195f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/b655d604adcd/fcad195f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/bc88cc8beafc/fcad195f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/fd30305899c1/fcad195f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/2bdfa4597abf/fcad195f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/b2ed943217b2/fcad195_ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/be646a8ad937/fcad195f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/10b2069557be/fcad195f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/fbfcf4f09176/fcad195f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/b655d604adcd/fcad195f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/bc88cc8beafc/fcad195f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/fd30305899c1/fcad195f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615f/10351670/2bdfa4597abf/fcad195f7.jpg
摘要

早期发现阿尔茨海默病对于制定预防性治疗策略至关重要。脑容量的可检测变化在疾病的致病进展过程中出现得相对较晚,但早期神经病理学引起的微观结构变化可能会导致磁共振信号的细微变化,可通过纹理分析进行量化。纹理分析可量化图像中的空间模式,如平滑度、随机性和异质性。我们研究了海马体(阿尔茨海默病病理学的早期部位)的磁共振成像纹理在认知障碍发作前是否对脑微观结构的变化敏感。我们还探讨了海马体纹理在阿尔茨海默病连续体中的纵向轨迹与海马体体积和其他生物标志物的关系。最后,我们评估了纹理在预测未来认知衰退方面的能力,超越了海马体体积。数据来自阿尔茨海默病神经成像计划。在3T T加权磁共振成像扫描上计算双侧海马体的纹理。293个纹理特征被缩减为五个主成分,这些主成分描述了认知未受损参与者中总方差的88%。我们评估了四个诊断组之间这些纹理成分和海马体体积的横断面差异:认知未受损的淀粉样蛋白β(=406);认知未受损的淀粉样蛋白β(=213);轻度认知障碍淀粉样蛋白β(=347);以及阿尔茨海默病痴呆淀粉样蛋白β(=202)。为了评估阿尔茨海默病连续体中海马体纹理的纵向变化,我们使用多元混合效应样条模型根据淀粉样蛋白PET和认知评分计算所有时间点的“疾病时间”。这被用作一个尺度,用于比较生物标志物的轨迹,包括海马体的体积和纹理。在数据的一个子集中对轨迹进行建模:认知未受损的淀粉样蛋白β(=345);认知未受损的淀粉样蛋白β(=173);轻度认知障碍淀粉样蛋白β(=301);以及阿尔茨海默病痴呆淀粉样蛋白β(=161)。我们在阿尔茨海默病的最早阶段发现了纹理成分4的差异,在认知未受损的淀粉样蛋白β和认知未受损的老年淀粉样蛋白β之间(科恩d=0.23,P=0.014)。在疾病连续体中,随着认知障碍的出现,其他纹理成分和海马体体积的差异在疾病后期出现(d=0.30 - 1.22,P<0.002)。纹理轨迹的纵向建模显示,虽然纹理的大多数元素在疾病过程中发展,但噪声降低了随时间跟踪个体纹理变化的敏感性。然而,至关重要的是,纹理提供了比单独体积更多的信息,以更准确地预测未来的认知变化(d=0.32 - 0.63,P<0.0001)。我们的结果支持在治疗干预可能最有效的时候,将纹理用作衡量脑健康的指标,对阿尔茨海默病病理学敏感。

相似文献

1
Longitudinal changes in hippocampal texture from healthy aging to Alzheimer's disease.从健康衰老到阿尔茨海默病海马体纹理的纵向变化。
Brain Commun. 2023 Jul 5;5(4):fcad195. doi: 10.1093/braincomms/fcad195. eCollection 2023.
2
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.血液磷酸化 tau 181 作为阿尔茨海默病的生物标志物:使用来自四个前瞻性队列的数据进行的诊断性能和预测模型研究。
Lancet Neurol. 2020 May;19(5):422-433. doi: 10.1016/S1474-4422(20)30071-5.
3
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.血浆神经丝轻链与阿尔茨海默病影像学生物标志物的阶段特异性关联。
Brain. 2020 Dec 1;143(12):3793-3804. doi: 10.1093/brain/awaa342.
4
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.18F-MK-6240 tau 缠结的纵向积累遵循 Braak 分期。
Brain. 2021 Dec 16;144(11):3517-3528. doi: 10.1093/brain/awab248.
5
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.描述阿尔茨海默病中淀粉样蛋白时间线上的脑 tau 与认知衰退。
Brain. 2024 Jun 3;147(6):2144-2157. doi: 10.1093/brain/awae116.
6
Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.认知健康的老年疑似非阿尔茨海默病病理生理学 (SNAP) 或阿尔茨海默病病理个体的临床和认知轨迹:一项纵向研究。
Lancet Neurol. 2016 Sep;15(10):1044-53. doi: 10.1016/S1474-4422(16)30125-9. Epub 2016 Jul 20.
7
Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.淀粉样蛋白病理和神经退行性变对认知正常成年人认知变化的影响。
Brain. 2018 Aug 1;141(8):2475-2485. doi: 10.1093/brain/awy150.
8
Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.在阿尔茨海默病神经影像倡议参与者中检测β-淀粉样蛋白阳性,并结合人口统计学、认知、磁共振成像和血浆生物标志物进行分析。
Brain Commun. 2021 Feb 2;3(2):fcab008. doi: 10.1093/braincomms/fcab008. eCollection 2021.
9
Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.常染色体显性阿尔茨海默病的神经影像学和临床标志物的纵向评估:一项前瞻性队列研究。
Lancet Neurol. 2015 Aug;14(8):804-813. doi: 10.1016/S1474-4422(15)00135-0. Epub 2015 Jun 29.
10
Tau accumulation and its spatial progression across the Alzheimer's disease spectrum.tau蛋白积累及其在阿尔茨海默病谱系中的空间进展。
Brain Commun. 2024 Feb 7;6(1):fcae031. doi: 10.1093/braincomms/fcae031. eCollection 2024.

引用本文的文献

1
Texture-based morphometry in relation to apolipoprotein ε4 genotype, ageing and sex in a midlife population.基于纹理的形态计量学与中年人群载脂蛋白 E4 基因型、衰老和性别有关。
Hum Brain Mapp. 2024 Aug 1;45(11):e26798. doi: 10.1002/hbm.26798.
2
Beyond Macrostructure: Is There a Role for Radiomics Analysis in Neuroimaging ?超越宏观结构:影像组学分析在神经影像学中有作用吗?
Magn Reson Med Sci. 2024 Jul 1;23(3):367-376. doi: 10.2463/mrms.rev.2024-0053. Epub 2024 Jun 14.

本文引用的文献

1
Independent and reproducible hippocampal radiomic biomarkers for multisite Alzheimer's disease: diagnosis, longitudinal progress and biological basis.用于多中心阿尔茨海默病的独立且可重复的海马区影像组学生物标志物:诊断、纵向进展及生物学基础
Sci Bull (Beijing). 2020 Jul 15;65(13):1103-1113. doi: 10.1016/j.scib.2020.04.003. Epub 2020 Apr 3.
2
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson's disease.帕金森病发病年龄对症状谱、治疗特征和健康相关生活质量的影响。
Sci Rep. 2022 Jan 11;12(1):526. doi: 10.1038/s41598-021-04356-8.
3
Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status.
血浆磷酸化 tau181 作为阿尔茨海默病淀粉样蛋白、tau 和 FDG PET 状态的预测生物标志物。
Transl Psychiatry. 2021 Nov 13;11(1):585. doi: 10.1038/s41398-021-01709-9.
4
Clinica: An Open-Source Software Platform for Reproducible Clinical Neuroscience Studies.Clinica:用于可重复临床神经科学研究的开源软件平台。
Front Neuroinform. 2021 Aug 13;15:689675. doi: 10.3389/fninf.2021.689675. eCollection 2021.
5
Prediction of the progression from mild cognitive impairment to Alzheimer's disease using a radiomics-integrated model.使用放射组学整合模型预测从轻度认知障碍到阿尔茨海默病的进展。
Ther Adv Neurol Disord. 2021 Jul 15;14:17562864211029551. doi: 10.1177/17562864211029551. eCollection 2021.
6
Simultaneous modeling of Alzheimer's disease progression via multiple cognitive scales.通过多个认知量表对阿尔茨海默病进展进行同步建模。
Stat Med. 2021 Jun 30;40(14):3251-3266. doi: 10.1002/sim.8932. Epub 2021 Apr 14.
7
Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach.使用放射组学方法预测轻度认知障碍患者的淀粉样蛋白阳性。
Sci Rep. 2021 Mar 26;11(1):6954. doi: 10.1038/s41598-021-86114-4.
8
Statistical Disease Progression Modeling in Alzheimer Disease.阿尔茨海默病的统计疾病进展建模
Front Big Data. 2020 Aug 12;3:24. doi: 10.3389/fdata.2020.00024. eCollection 2020.
9
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease.厘清阿尔茨海默病中淀粉样蛋白-β和 tau 与突触和轴突丢失的关联。
Brain. 2021 Feb 12;144(1):310-324. doi: 10.1093/brain/awaa395.
10
Quality Reporting of Radiomics Analysis in Mild Cognitive Impairment and Alzheimer's Disease: A Roadmap for Moving Forward.基于影像组学分析的轻度认知障碍与阿尔茨海默病的质量报告:前行的蓝图。
Korean J Radiol. 2020 Dec;21(12):1345-1354. doi: 10.3348/kjr.2020.0715. Epub 2020 Oct 30.